GOLD SPONSOR

Founded in 1998, Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. Our dedicated commitment to continuous innovation has resulted in an unrivalled pipeline of novel therapies.

We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.